Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems
- 18 February 2017
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 34 (4) , 1-16
Abstract
Drug therapy for non-small cell lung cancer consists mainly of platinum-based chemotherapy regimens. However, toxicity, drug resistance, and high risk of death have been seen in the clinic, which means there is a need for optimizing the use of medications. Platinum resistance could be mediated by a series of DNA repair pathways, and therefore, these pathways should be taken into account for optimizing drug using. The goal of pharmacogenomics is to elucidate genetic factors, such as DNA repair genes, which might underlie drug efficacy and effectiveness, and to improve therapeutic effects or guide personalized therapy as well. Here, we reviewed the current knowledge of pharmacogenomic data on DNA repair systems and examined whether they could be further translated into the clinic with evidence-based perspectives.Keywords
Funding Information
- National Natural Science Foundation of China (81573463)
- Hunan Provincial Natural Science Foundation of China Grant (2015JJ1024)
- Innovation project of Central South University (ZY2016764)
This publication has 96 references indexed in Scilit:
- XRCC3 Thr241Met Is Associated with Response to Platinum-Based Chemotherapy but Not Survival in Advanced Non-Small Cell Lung CancerPLOS ONE, 2013
- Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- XRCC3 Thr241Met Polymorphism and Clinical Outcomes of NSCLC Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2013
- Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) PatientsPLOS ONE, 2012
- HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancerCarcinogenesis, 2012
- Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer PatientsPLOS ONE, 2012
- The potential of exploiting DNA-repair defects for optimizing lung cancer treatmentNature Reviews Clinical Oncology, 2012
- Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer PatientsJournal of Thoracic Oncology, 2011
- DNA Repair: From Genome Maintenance to Biomarker and Therapeutic TargetClinical Cancer Research, 2011